Kowa and DKSH Debut Triglycerides Lowering Medicine, Parmodia®, in Malaysia

Petaling Jaya, Malaysia, January 24, 2025 – DKSH Business Unit Healthcare, a strategic partner for companies seeking to grow their healthcare business in Asia and beyond, is proud to announce the expansion of its partnership with Kowa Company, Ltd., a global enterprise with various business fields including the manufacturing and sales of medicines to Malaysia.

Under the extended agreement, DKSH Malaysia Healthcare will undertake the responsibility for providing comprehensive Market Expansion Services, including marketing and sales, for the newly launched triglycerides lowering drug, Parmodia® film-coated tablets 0.1mg (MAL23056003AZ).

Since 2022, DKSH Malaysia Healthcare has been distributing a range of Kowa products, Parmodia®, introduced in Malaysia in February 2024, marks the latest addition to Kowa’s product lineup and repre-sents a new class of medications known as selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα).

Parmodia® is indicated as an adjunctive therapy to diet or other nonpharmacological treatment such as exercise to reduce TG and to increase high density lipoprotein-cholesterol (HDL-C) in patients with dyslipidemia characterized by a high level of TG ≥150 mg/dL, particularly when there is evidence of associated risk such as hypertension and smoking.

Sandeep Tewari, Head Country Leadership and Vice President, Healthcare, DKSH Malaysia, added: “We eagerly anticipate the evolution of our collaboration with Kowa. This partnership symbolizes a joint commitment to innovation, growth, and delivering exceptional medical products to the Malaysian patients, underscoring our commitment to enriching people’s lives and providing healthcare for all.”